UPS Extends Complex Healthcare Logistics Lead with $48 Million Investment in Temperature-Controlled Freight Cross-Dock Facilities

Key Terms

cold-chain technical

A cold-chain is the refrigerated logistics system that keeps temperature-sensitive products—such as vaccines, biologic drugs, and perishable foods—within a controlled temperature range from production through storage and transport to the end user. Investors care because failures in this “continuous refrigerator” can destroy product value, trigger costly recalls or regulatory penalties, and require specialized infrastructure and ongoing operating costs that affect margins and growth potential.

iata ceiv pharma regulatory

IATA CEIV Pharma is a certification program from the International Air Transport Association that verifies airlines, freight forwarders, ground handlers and other logistics providers follow agreed standards and controls for transporting temperature- and condition-sensitive medicines and vaccines by air. For investors, CEIV certification signals lower risk of spoiled product, regulatory penalties or shipment delays and thus greater reliability and protection of revenue and reputation—like a trusted quality stamp for fragile pharmaceutical shipments.

mrna platforms medical

mRNA platforms are a set of technologies, manufacturing processes and know‑how used to design, produce and deliver medicines or vaccines that use messenger RNA as the active ingredient. Think of it as a flexible blueprint and factory that can be retooled to make different mRNA-based treatments quickly; investors watch these platforms because their efficiency, scalability, patent position and regulatory track record determine how fast and cheaply a company can bring multiple products to market and generate revenue.

glp-1 injectables medical

A class of injectable medicines that mimic a natural gut hormone to lower blood sugar and often reduce appetite and body weight; think of them as a thermostat that helps reset the body’s controls for blood sugar and hunger. They matter to investors because strong demand, pricing, regulatory approvals, patent protection, manufacturing capacity and safety data can drive large drug revenues or disrupt markets for diabetes and obesity treatments.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Global cold-chain network investment increases speed, visibility and end-to-end chain of custody for advanced therapies and other temperature-sensitive medicines

ATLANTA--(BUSINESS WIRE)--

UPS (NYSE: UPS), the world’s No. 1 provider of complex healthcare logistics, today announced its $48 million investment in 27 temperature-controlled freight cross-dock facilities around the globe. Located in key U.S. and international markets, including Europe, Asia and the Americas, these facilities are optimized for speed and short-term storage between air and ground movements – all while maintaining specific temperature requirements. The announcement strengthens UPS’s global cold-chain network as demand grows for medicines requiring strict temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius and frozen.

Industry demand for temperature-sensitive biologics is projected to expand at an 8.3% compound annual growth rate through 2033, reaching an estimated $39.1 billion, according to Growth Market Reports. Meeting this demand requires cold-chain expertise to maintain product quality and safety from manufacturing to patient.

“We have aligned our investments with our Healthcare customers’ specialized needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,” said Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS. “This effort – and all of our work in healthcare logistics – extends from a deep understanding that we’re doing more than moving packages. We are helping patients access the medications and treatments they need.”

Single Provider, Total Control: Integrated Freight Cross-Docks Reduce Risk

• 27 temperature-controlled freight cross-docks create seamless movement across transportation modes. All facilities are compliant with IATA CEIV Pharma certification, an industry-recognized standard for pharmaceutical handling and quality.
• A single integrated network eliminates handoffs between providers, reducing risk and increasing control.
• Greater accountability and real-time oversight protect high-value, temperature-sensitive therapies from excursion and disruption.
• 24/7/365 control tower proactively monitors shipments, flags risks and enables rapid intervention to keep critical products moving.

Rise of Advanced Therapies Accelerates Demand for Precision Cold-Chain Solutions

The rapidly growing biologics pipeline is increasing complexity across cold-chain logistics. According to PharmaSource, roughly one in three newly approved drugs today is a biologic more than 85% of those requiring temperature-controlled handling.

As therapies like cell and gene treatments, mRNA platforms and GLP-1 injectables come to market, healthcare supply chains are becoming more complex and risk-sensitive. Temperature excursions are a key driver of that risk, with cold-chain failures estimated to cost up to $35 billion annually and, according to WHO, contributing to up to 50% of global vaccine waste.

“Biologics and personalized treatments are driving better, more targeted care for patients,” said John Bolla, President of UPS Healthcare. “These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes.”

Acquisition to Advantage: Investments Are Scaling Complex Healthcare Logistics

UPS’s cross-dock expansion builds on a long-term investment in complex healthcare logistics, strengthened through acquisitions including Bomi Group, Frigo Trans and BPL in Europe and Andlauer Healthcare Group in North America. More recently, UPS expanded its Incheon, Korea air hub to support fast-growing pharmaceutical trade flows, as South Korea imported nearly $9.7 billion in pharmaceutical products in 2025, according to Observatory of Economic Complexity data.

The result is a more responsive supply chain that keeps high-value, time- and temperature-sensitive healthcare shipments moving seamlessly across air, ocean, ground and final mile. As demand grows, UPS’s integrated network is built to manage this complexity today and scale for what’s ahead.

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2025 revenue of $88.7 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 460,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. More information can be found at www.ups.com, about.ups.com and investors.ups.com.

About UPS Healthcare

UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 19.2+ million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices, and lab and clinical trial logistics. UPS Healthcare's global infrastructure, its UPS® Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Visit Healthcare.ups.com for more information.

Sources: Growth Market Reports; PharmaSource; Westwell Lab; World Health Organization; Observatory of Economic Complexity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260622325874/en/

UPS Media Relations
pr@ups.com

Source: UPS